1. Home
  2. SATS vs ICUCW Comparison

SATS vs ICUCW Comparison

Compare SATS & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SATS
  • ICUCW
  • Stock Information
  • Founded
  • SATS 2007
  • ICUCW N/A
  • Country
  • SATS United States
  • ICUCW United States
  • Employees
  • SATS N/A
  • ICUCW 19
  • Industry
  • SATS Telecommunications Equipment
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • Sector
  • SATS Consumer Discretionary
  • ICUCW Health Care
  • Exchange
  • SATS Nasdaq
  • ICUCW Nasdaq
  • Market Cap
  • SATS N/A
  • ICUCW N/A
  • IPO Year
  • SATS 2007
  • ICUCW 2021
  • Fundamental
  • Price
  • SATS $32.59
  • ICUCW $0.03
  • Analyst Decision
  • SATS Hold
  • ICUCW
  • Analyst Count
  • SATS 6
  • ICUCW 0
  • Target Price
  • SATS $23.70
  • ICUCW N/A
  • AVG Volume (30 Days)
  • SATS 2.5M
  • ICUCW N/A
  • Earning Date
  • SATS 08-01-2025
  • ICUCW N/A
  • Dividend Yield
  • SATS N/A
  • ICUCW N/A
  • EPS Growth
  • SATS N/A
  • ICUCW N/A
  • EPS
  • SATS N/A
  • ICUCW N/A
  • Revenue
  • SATS $15,680,431,000.00
  • ICUCW N/A
  • Revenue This Year
  • SATS N/A
  • ICUCW N/A
  • Revenue Next Year
  • SATS N/A
  • ICUCW N/A
  • P/E Ratio
  • SATS N/A
  • ICUCW N/A
  • Revenue Growth
  • SATS N/A
  • ICUCW N/A
  • 52 Week Low
  • SATS $14.79
  • ICUCW N/A
  • 52 Week High
  • SATS $34.20
  • ICUCW N/A
  • Technical
  • Relative Strength Index (RSI)
  • SATS 68.15
  • ICUCW N/A
  • Support Level
  • SATS $28.89
  • ICUCW N/A
  • Resistance Level
  • SATS $34.20
  • ICUCW N/A
  • Average True Range (ATR)
  • SATS 1.36
  • ICUCW 0.00
  • MACD
  • SATS -0.01
  • ICUCW 0.00
  • Stochastic Oscillator
  • SATS 75.42
  • ICUCW 0.00

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: